CoRegen's main product is a cutting-edge cancer therapy designed to modify regulatory T cells (Tregs) with the aim of eliminating tumors and preventing their recurrence. The therapy focuses on effectively enhancing the immune response against cancer cells.

• ·Simultaneous targeting of multiple immune checkpoint genes
• ·Ability to completely eradicate established tumors in preclinical studies
• ·Prevention of tumor recurrence without toxicity or off-target effects